Overactive bladder or non-neurogenic overactive bladder is a syndrome characterized by urinary urgency, frequency, nocturia and urgency incontinence.
It is not a disease but a symptom complex that generally is not a life-threatening condition. It is also known as bladder spasms.
Urgency is the complaint of sudden, compelling desire to pass urine that is difficult to deny. It is considered a hallmark symptom of overactive bladder.
Frequency is usually micturition of >7 episodes during waking hours.
Nocturia is the interruption of sleep one or more times because of the need to void.
Urgency incontinence is the involuntary leakage of urine associated with a sudden compelling desire to void.
Apostolidis A. Antimuscarinics in the treatment of OAB: is there a first-line and a second-line choice?. Current Drug Therapies. 2015 May;15(4). doi: 10.2174/1389450116666150518102021. PMID: 25981605
Arnold J, McLeod N, Thani-Gasalam, et al; Australian Family Physicians (incorporating Annals of General Practice); The Royal Australian College of General Practitioners. Overactive bladder syndrome - Management and treatment options. Aust Fam Physician. 2012 Nov;41(11):878-883. http://www.racgp.org.au/download/Documents/AFP/2012/November/201211arnold.pdf. PMID: 23145420
Chapple C, Oelke M, Kapalan S, et al. Fesoterodine clinical efficacy and safety for the treatment of overactive bladder in relation to patient profiles: a systematic review. Curr Med Res Opin. 2015 Jun;31(6):1201-1243. doi: 10.1185/03007995.2015.1032917. PMID: 25798911
Chapple CR, Cardozo L, Nitti VW, et al. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014 Jan;33(1):17-30. doi: 10.1002/nau.22505. PMID: 24127366
Ellsworth P, Vincent M. Overactive bladder. eMedicine. http://emedicine.medscape.com/article/459340-overview. Apr 2014.
European Association of Neurology. New drug therapies for LUTS discussed at the last Plenary Session. EAU. http://uroweb.org/new-drug-therapies-for-luts-discussed-at-the-last-plenary-session. Mar 2013.
Filipetto F, Fulda K, HolthusenA, et al. The patient perspective on overactive bladder: a mixed methods needs assessment. BMC Family Practice. 2014 May;15:96. doi: 10.1186/147122961596.
Foster H. Health insights: overactive bladder. HealthNation. http://www.healthination.com/digestive-urinary/insights-overactive-bladder.
Gill P, Gewal N. Mirabegron: first β3 agonist in treatment of overactive bladder. Int J Basic Clin Pharmacol. 2012 Sep;1(2):120-121. doi: 10.5455/23192003.ijbcp002212.
Gormley A, Lightner D, Burgio K, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline. AUA. http://www.auanet.org/common/pdf/education/clinical-guidance/Overactive-Bladder.pdf. 2014.
Hobbs C, Henderson J, Foley S. Results of intravesical botulinum toxin A in men with idiopathic overactive bladder symptoms. Journal of Clinical Urology. 2014 Aug;8(2):104-109. doi: 10.1177/2051415814546034.
Jayarajan J, Radomski SB. Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life. Res Rep Urol. 2013 Dec;6:1-16. doi: 10.2147/RRU.S40034. PMID: 24400248
Maman K, Aballea S, Nazir J. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol. 2014 Apr;65(4):755-765. doi: 10.1016/j.eururo.2013.11.010. PMID: 24275310
McKeage K. Propiverine: a review of its use in the treatment of adults and children with overactive bladder associated with idiopathic or neurogenic detrusor overactivity, and in men with lower urinary tract symptoms. Clin Drug Investig. 2013 Jan;33(1):71-91. doi: 10.1007/s40261-012-0046-9. PMID: 23288694
Mo Q, Wang Y, Ye Y, et al. Acupuncture for adults with overactive bladder: a systematic review protocol. BMJ Open. 2015 Jan;5(1):e006756. doi: 10.1136/bmjopen-2014-006756. PMID: 25573525
Mudiwa L. The latest amendments to the overactive bladder clinical practice guidelines. Irish Medical Times. http://www.imt.ie/clinical/2014/09/the-latest-amendments-to-the-overactive-bladder-clinical-practice-guidelines.html. Jun 2013.
National Clinical Guideline Centre. Clinical Guideline 148; Methods, evidence and recommendations; Commissioned by the National Institute for Health and Clinical Excellence. Urinary incontinence in neurological disease: management of lower urinary tract dysfunction in neurological disease. Final Version. NCGC. http://www.nice.org.uk/guidance/cg148/resources/cg148-urinary-incontinence-in-neurological-disease-full-guideline3. Aug 2012.
The Cystitis & Overactive Bladder Foundation. Overactive bladder. COB. http://www.cobfoundation.org/overactive-bladder.
U.S. Food and Drug Administration. FDA approves Botox to treat overactive bladder. US FDA. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336101.htm.
van Rey F, Heesakkers J. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol. 2011 Mar;2011(2011):1-4. doi: 10.1155/2011/834753. PMID: 21687581
Yeo EK, Hasim H, Abrams P. New therapies in the treatment of overactive bladder. Expert Opin Emerg Drugs. 2013 Sep;18(3):319-337. doi: 10.1517/14728214.2013.823156. PMID: 23885696